XBiotech Bilan de santé

Santé financière contrôle des critères 3/6

XBiotech possède un total de capitaux propres de $192.1M et une dette totale de $10.0M, ce qui porte son ratio d'endettement à 5.2%. Son actif total et son passif total sont $209.9M et de $17.7M.

Informations clés

5.2%

Ratio d'endettement

US$10.00m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$183.12m
Fonds propres	US$192.12m
Total du passif	US$17.74m
Total des actifs	US$209.85m

Mises à jour récentes de la santé financière

Recent updates

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

Aug 30

XBiotech: Several Shots On Goal In Big Target Market Indications

May 24

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

May 13

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

Feb 09

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

Oct 25

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

Jun 16

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

May 11

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

Mar 18

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

Jan 08

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

Nov 19

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de XBIT ( $185.0M ) dépassent ses passifs à court terme ( $16.0M ).

Passif à long terme: Les actifs à court terme de XBIT ( $185.0M ) dépassent ses passifs à long terme ( $1.7M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: XBIT dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de XBIT est passé de 0% à 5.2% au cours des 5 dernières années.

Couverture de la dette: Le flux de trésorerie opérationnel de XBIT est négatif, par conséquent la dette n'est pas bien couverte.

Couverture des intérêts: Données insuffisantes pour déterminer si les paiements d'intérêts de XBIT sur sa dette sont bien couverts par l'EBIT.

XBiotech Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

Recent updates

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech: Several Shots On Goal In Big Target Market Indications

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

XBiotech Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

XBiotech Inc. announced that it expects to receive $10 million in funding

Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke

Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

First half 2023 earnings released: US$0.41 loss per share (vs US$0.56 loss in 1H 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$1.08 loss per share (vs US$0.58 loss in FY 2021)

XBiotech Inc. Announces Executive Changes

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

Insufficient new directors

Third quarter 2022 earnings released: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

XBiotech Inc. Announces First Patient Enrolled into the French National Cancer Institute Sponsored Phase I/Ii/Iii Clinical Study for Natrunix™ Therapy for Colorectal Cancer

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.17 loss in 2Q 2021)

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 2000 Dynamic Index

XBiotech Announces Successful Completion of Phase I Portion of Pancreatic Cancer Study

XBiotech Inc., Annual General Meeting, Jun 22, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Insufficient new directors

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.087 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 2Q 2020)

Board Member exercised options to buy US$452k worth of stock.

XBiotech Inc. Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer

Founder exercised options to buy US$9.8m worth of stock.

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

New 90-day high: US$19.83

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

New 90-day low: US$16.72

Independent Director notifies of intention to sell stock

Xbiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-Covid-19 Therapeutic Cocktail

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections

New 90-day high - US$19.95

New 90-day high - US$19.57

New 90-day high - US$16.08

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 3000 Growth Index

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines